ArticleCureus2026
Cholestatic Jaundice Without Hepatomegaly as the Initial Manifestation of Hepatic Amyloid Light-Chain (AL) Amyloidosis: A Case of Rapid Multiorgan Failure.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic amyloid light-chain (AL) amyloidosis is a rare plasma cell disorder characterized by extracellular deposition of misfolded immunoglobulin light chains, resulting in progressive organ dysfunction. Although hepatic involvement is recognized in AL amyloidosis, it is often clinically silent or presents with hepatomegaly (liver enlargement) and cholestatic liver enzyme abnormalities. Severe cholestatic jaundice as the initial and dominant manifestation is uncommon, particularly in the absence of hepatomegaly or radiographic biliary obstruction. We report a 63-year-old woman with limited prior healthcare engagement who presented with persistent left ankle pain after a minor twisting injury and was incidentally found to have painless progressive jaundice. Initial laboratory evaluation showed a marked cholestatic pattern of liver injury, including alkaline phosphatase greater than 2300 U/L, total bilirubin of 11.8 mg/dL, direct bilirubin of 8.7 mg/dL, and gamma-glutamyl transferase of 1152 U/L, with disproportionately lower transaminase elevation. Imaging showed cholelithiasis but no biliary obstruction, ductal dilation, focal hepatic lesion, or hepatomegaly. Serologic evaluation for common hepatobiliary causes was unrevealing. Liver biopsy demonstrated amyloidosis predominantly around the portal veins, canalicular and chronic cholestasis, periportal fibrosis, and focal bridging fibrosis. Hematologic evaluation revealed an IgG lambda monoclonal protein, lambda-predominant free light-chain elevation, and bone marrow involvement by a lambda-restricted plasma cell neoplasm, establishing systemic AL amyloidosis with hepatic involvement. Despite initiation of attenuated daratumumab, bortezomib, and dexamethasone therapy, the patient developed rapidly progressive hepatic dysfunction, decompensated heart failure, acute kidney injury, refractory volume overload, and anuric renal failure. She ultimately elected comfort-focused care and was discharged to hospice. This case highlights hepatic AL amyloidosis as an important diagnostic consideration in unexplained cholestatic jaundice, even without hepatomegaly or biliary obstruction. Early recognition is essential, as severe hepatic dysfunction with multisystem involvement carries a poor prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.